How is NanoFlashing designed into medical devices?

Which finished-product evidence supports a medical-use, implant, sterility or patient-contact representation, if any is made?

The label for the NanoFlashing™ Air Filter states that the filter is not a medical device and is not intended to diagnose, treat, cure or prevent disease.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. They also state: “Results of tests on a material, component, sample, or prototype apply to that item. The safety, efficacy, suitability, durability, compatibility, manufacturability, scalability, and performance of a finished product are confirmed by testing that finished product.” and that images and descriptions may show concepts or prototypes, which are not specifications, instructions, validation reports, recommendations, warranties, offers, promises, or commitments.

The company publishes no finished-product evidence for a medical use, an implant, a sterility claim or patient contact, because the Medical page describes a Research Application.

What the company does publish is named on the Validation page: the pathogens tested, the conditions tested, the institutes that tested them, the peer-reviewed paper by Gong, Or, Sze et al., Microbiology Spectrum 12(9), e0409723, American Society for Microbiology, doi:10.1128/spectrum.04097-23, and, for the air-filtration, certification and safety records, the issuing body and the number for each.

Source: C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/; C-POLAR — NanoFlashing™ Medical, https://cpolar.tech/medical/; C-POLAR — Validation, https://cpolar.tech/validation/; NanoFlashing™ Air Filter label, About this product. A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Reviewed on 6 October 2026.

Would integrating the material change the intended use of an existing medical device?

What the intended use of a device is, and whether a change alters it, is determined by the device's own sponsor under the rules that apply to that device.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. They also state: “Results of tests on a material, component, sample, or prototype apply to that item. The safety, efficacy, suitability, durability, compatibility, manufacturability, scalability, and performance of a finished product are confirmed by testing that finished product.” and that images and descriptions may show concepts or prototypes, which are not specifications, instructions, validation reports, recommendations, warranties, offers, promises, or commitments. The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.” The Terms also state: “Nothing on the Site authorizes anyone to manufacture, integrate, market, resell, or describe a product as C-POLAR-enabled.”

Source: C-POLAR — Terms of Use, sections 4 and 5, https://cpolar.tech/terms/; C-POLAR — NanoFlashing™ Medical, https://cpolar.tech/medical/.

Reviewed on 21 September 2026.

Does the duration of patient contact change the required biological evaluation?

What a device sponsor must hold or submit is decided by that sponsor and by the authority it submits to, and the company gives no regulatory advice.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.”

What the company states about its own testing is on the Validation page. The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324. Those are studies of the material under the guidelines named, and they are not a biological evaluation of a finished device.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 4 and 5, https://cpolar.tech/terms/. A copy may be made available on our review of the request.

Reviewed on 21 September 2026.

Can NanoFlashing tolerate the intended sterilisation process?

The conditions listed on the Validation page are heavy dust loaded, fast air flow, used filter for 1 year, after 60 washes, after 2 years of storage, and after 60C for 64 days. A sterilisation process is not among those conditions, and the company publishes no sterilisation study or compatibility statement for one. The Terms of Use state: “A reported result describes only what the identified test found.” The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses.

A materials review is arranged in writing, through [email protected] on the Contact page.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/. A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Reviewed on 6 October 2026.

Does sterilisation alter the material's functional properties even if it remains physically intact?

NanoFlashing™ is a permanent positive polarity engineered into filter media itself. It is a physical property of the filter. The conditions listed on the Validation page are heavy dust loaded, fast air flow, used filter for 1 year, after 60 washes, after 2 years of storage, and after 60C for 64 days. A sterilisation process is not among those conditions, and the company publishes no before-and-after measurement for one. The Terms of Use state: “A reported result describes only what the identified test found.” The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses.

A materials review is arranged in writing, through [email protected] on the Contact page.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/. A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Reviewed on 6 October 2026.

Can the material be supplied with documented cleanliness limits appropriate to the proposed device?

A cleanliness limit for delivered material is a term of the agreement that governs the delivery; terms of that kind are agreed in writing between the parties to a supply agreement.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses.

The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.” The company publishes no cleanroom classification and no packaging cleanliness class, because a cleanliness limit is agreed in writing between the parties to a supply agreement. A materials review is arranged in writing, through [email protected] on the Contact page.

Source: C-POLAR — Terms of Use, sections 4, 5 and 6, https://cpolar.tech/terms/. A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Reviewed on 6 October 2026.

Would packaging aging affect sterile-barrier integrity for a device containing the material?

The company publishes no packaging-ageing result and no sterile-barrier result, and the Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The Terms of Use state: “A reported result describes only what the identified test found.” A question about a particular product or market can be sent to [email protected] or +1 604 630 6830.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Does the material interact with drugs passing through a proposed fluid-contact device?

The company publishes no interaction study, and the Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The Terms of Use state: “A reported result describes only what the identified test found.” A question about a particular product or market can be sent to [email protected] or +1 604 630 6830.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Could it bind a therapeutic substance that the device is meant to deliver?

What the company states about the mechanism is that NanoFlashing™ attracts negatively charged particles through electrostatic attraction, and that the filter captures airborne particles mechanically and by electrostatic attraction. The company publishes no binding study, and the Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The Terms of Use state: “A reported result describes only what the identified test found.” A question about a particular product or market can be sent to [email protected] or +1 604 630 6830.

Source: C-POLAR — NanoFlashing™, https://cpolar.tech/nanoflashing/; Statement of Classification for the NanoFlashing™ Air Filter, section 2.5, issued by NF Technical Products Inc.; C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Does a proposed wound-contact use require evidence about healing rather than surface performance alone?

The Terms of Use state: “Laboratory results report the organisms, particles, and endpoints that were measured. C-POLAR makes no clinical or medical claim from them.” They also state: “Do not use Site Content to diagnose, treat, or make a patient-care or infection-control decision.”

The label for the NanoFlashing™ Air Filter states that the filter is not a medical device and is not intended to diagnose, treat, cure or prevent disease.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The Terms also state: “Do not delay or replace professional care because of Site Content.” The company publishes no wound-contact result and no healing outcome of any kind. A laboratory result on an organism is not a medical conclusion.

Source: C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/; NanoFlashing™ Air Filter label, About this product.

Reviewed on 6 October 2026.

Can the material change a device's electrical or electromagnetic safety assessment?

The Terms of Use state: “Each reported result belongs to the C-POLAR material, component, or prototype that was tested. The maker of a finished product confirms the performance of that product, because construction, processing, storage, wear, cleaning, other components, and actual use are part of it.”

The filter is passive. It draws no power, and it has no power supply, electrode, lamp or reservoir. The polarity is a positive electric charge at rest. A charge is a physical property. It is not a substance or a mixture of substances. This site publishes no electrical-safety or electromagnetic-compatibility test for any product.

The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.” Whether a device's electrical assessment changes is determined by the sponsor of that device.

Source: Statement of Classification for the NanoFlashing™ Air Filter, sections 2.2, 2.4 and 3.6, issued by NF Technical Products Inc.; C-POLAR — Terms of Use, sections 3 and 5, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Would a ventilator accessory containing the material alter delivered pressure or volume?

The Terms of Use state: “Each reported result belongs to the C-POLAR material, component, or prototype that was tested. The maker of a finished product confirms the performance of that product, because construction, processing, storage, wear, cleaning, other components, and actual use are part of it.”

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The company publishes no result for a ventilator accessory and no pressure or volume measurement for any product.

The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.” They also state: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” NanoFlashing™ is a technology; the name, rating and sale of a product that carries it are set by that product's maker and seller.

Source: C-POLAR — Terms of Use, sections 3, 4 and 5, https://cpolar.tech/terms/; C-POLAR — NanoFlashing™ Medical, https://cpolar.tech/medical/.

Reviewed on 6 October 2026.

Does a device sponsor need separate evidence for extractables and leachables?

What a device sponsor must hold or submit is decided by that sponsor and by the authority it submits to, and the company gives no regulatory advice.

The company publishes no extractables study and no leachables study for a device; the Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.” The company's statement that the filter emits nothing into the air passing through it is about a filter in use, and it is not an extractables or leachables result. A question about a particular product or market can be sent to [email protected] or +1 604 630 6830.

Source: Statement of Classification for the NanoFlashing™ Air Filter, section 2.4, issued by NF Technical Products Inc.; C-POLAR — Terms of Use, section 5, https://cpolar.tech/terms/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 6 October 2026.

Can a material supplier support a regulator's confidential review without disclosing trade secrets publicly?

A review that needs more than the company's published pages is arranged in writing, and material sent through a general Site form is not treated as confidential.

The Terms of Use state: “Do not send confidential, proprietary, patient, or trade-secret information through a general Site form. C-POLAR does not accept a duty of confidentiality for material sent through a general Site form unless a Separate Agreement covering that material is already in force.” A Separate Agreement is a written agreement signed by an authorized C-POLAR officer.

Each numbered report the company cites is named with its institution and number, and with its date and standard where the report gives them.

Source: C-POLAR — Terms of Use, sections 1 and 10, https://cpolar.tech/terms/; C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 21 September 2026.

Would reprocessing a reusable medical device alter the supported NanoFlashing function?

The one article the company labels is replaced rather than reprocessed: “Do not wash, vacuum, brush, blow out or reuse this filter.”

The conditions listed on the Validation page are heavy dust loaded, fast air flow, used filter for 1 year, after 60 washes, after 2 years of storage, and after 60C for 64 days. The Terms of Use state: “A reported result describes only what the identified test found.” A reprocessing cycle for a reusable device is not among those conditions, and the company publishes no reprocessing study, because the Medical devices chapter describes Research Applications: the Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The Terms of Use also state: “Results of tests on a material, component, sample, or prototype apply to that item. The safety, efficacy, suitability, durability, compatibility, manufacturability, scalability, and performance of a finished product are confirmed by testing that finished product.”

Source: NanoFlashing™ Air Filter label, Directions for Use; C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Is the material's quality agreement compatible with the device maker's change-control obligations?

For a prospective partner, a commitment from C-POLAR is one stated in a Separate Agreement, which is a written agreement signed by an authorized C-POLAR officer.

The Terms of Use state that accessing the Site or contacting C-POLAR through the Site does not create a partnership, agency, joint venture, distribution right, supply commitment, license, exclusive right, or other business relationship, and that a prospective partner may rely only on a commitment stated in a Separate Agreement. C-POLAR publishes no quality agreement and no change-notification commitment on the Site, and the Terms of Use also state that where these Terms conflict with a Separate Agreement or an express written C-POLAR warranty, that document controls.

Source: C-POLAR — Terms of Use, sections 1, 5 and 6, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Can the device manufacturer trace implanted or long-term-contact components to a specific supplied lot?

Production records and release decisions belong to the manufacturing partner that makes the product, and C-POLAR publishes none of them.

Every commercial NanoFlashing™ product is made by a manufacturing partner, in their facility, in their format, and lot identification on delivered material is a term of the agreement that governs the delivery. The Medical devices chapter describes a Research Application, and it does not describe a finished product currently available from C-POLAR for that use.

What a device manufacturer must trace, and how far back, is decided by that manufacturer under the rules that apply to it.

Source: C-POLAR — About, https://cpolar.tech/about/; C-POLAR — Terms of Use, sections 4 and 6, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Does the product's design history identify the risk created by adding the NanoFlashing material?

The Terms of Use state: “Each reported result belongs to the C-POLAR material, component, or prototype that was tested. The maker of a finished product confirms the performance of that product, because construction, processing, storage, wear, cleaning, other components, and actual use are part of it.”

A design history file belongs to the manufacturer that opened it, and C-POLAR publishes none. The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.” They also state: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” The Medical devices chapter describes a Research Application, and it does not describe a finished product currently available from C-POLAR for that use.

Source: C-POLAR — Terms of Use, sections 3, 4 and 5, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Would a clinical investigation be needed for the proposed device claim?

What a device sponsor must hold or submit is decided by that sponsor and by the authority it submits to, and the company gives no regulatory advice.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The Terms of Use state: “Laboratory results report the organisms, particles, and endpoints that were measured. C-POLAR makes no clinical or medical claim from them.” They also state: “Do not use Site Content to diagnose, treat, or make a patient-care or infection-control decision.” The company publishes no clinical investigation; what the company has published is laboratory testing, named on its Validation page with the institutions and the conditions tested.

A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Source: C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/; C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — NanoFlashing™ Medical, https://cpolar.tech/medical/.

Reviewed on 6 October 2026.

Can a component supplier's safety testing replace any part of the finished device's usability assessment?

The Terms of Use state: “Each reported result belongs to the C-POLAR material, component, or prototype that was tested. The maker of a finished product confirms the performance of that product, because construction, processing, storage, wear, cleaning, other components, and actual use are part of it.”

They also state: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” The company publishes no usability study, no comprehension test and no record of instructions tried with first-time users, because a usability assessment is made on the finished product, with its own users, and no material test replaces any part of it. The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.”

Source: C-POLAR — Terms of Use, sections 3 and 5, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Does the FDA's medical-device clearance pathway (510(k)) apply to the NanoFlashing™ Medical vertical?

The Medical devices chapter describes a Research Application, and the company's two classification statements, under FIFRA in the United States and under Regulation (EU) No 528/2012, are written for the NanoFlashing™ Air Filter, a panel air filter for forced-air heating, ventilation and air-conditioning systems.

The company publishes no FDA position, 510(k) or other, for the Medical vertical, and the Terms of Use state: “As of the Effective Date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications. They do not describe finished products currently available from C-POLAR for those uses.” The Medical page states: “The NanoFlashing™ Medical Device has a permanent positive polarity, a fixed positive charge.” The Terms of Use also state: “Results of tests on a material, component, sample, or prototype apply to that item. The safety, efficacy, suitability, durability, compatibility, manufacturability, scalability, and performance of a finished product are confirmed by testing that finished product.”

Source: C-POLAR — Terms of Use, section 4, https://cpolar.tech/terms/; C-POLAR — NanoFlashing™ Medical, https://cpolar.tech/medical/; Statement of Classification for the NanoFlashing™ Air Filter, section 1.2, issued by NF Technical Products Inc.; Statement of Regulatory Status for the NanoFlashing™ Air Filter, section 1.2, C-POLAR Technologies, Inc., 11 September 2026.

Reviewed on 6 October 2026.